Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial : B-240

Details

Serval ID
serval:BIB_C4482869A3A1
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial : B-240
Title of the conference
ECR 2010, 22nd European Congress of Radiology
Author(s)
Vogl T., Lee C., Lencioni R., Malagari K., Pilleul F., Denys A., Watkinson A., Lammer J.
Address
Vienna, Austria, March 4-8, 2010
ISBN
1869-4101
Publication state
Published
Issued date
2010
Volume
Vol. 1
Series
Insights into Imaging
Pages
S183
Language
english
Abstract
Purpose: To evaluate the toxicity focussing on hepatic, gastrointestinal and cardiac parameters following PRECISION TACE with DC Bead? versus conventional transarterial chemoembolization (cTACE) in the treatment of intermediate-stage hepatocellular carcinoma (HCC).
Methods and Materials: This prospective, randomized, multicentre study was
conducted under best practice trial management and authorized by local institutional
review boards. Informed consent was obtained. 212 patients (185 men/27 women;
mean: 67 years) were randomized to be treated with DC Beads? or cTACE. The
majority of both groups presented in a more advanced stage. Safety was measured
by rate of adverse events (South West Oncology Group criteria) and changes in
laboratory parameters. Cardiotoxicity was assessed by means of left ventricular
ejection fraction (LVEF) in MRI or echocardiography. The results of the two groups
were compared using the chi-square test and Student`s t-test.
Results: Mean maximum alanine transaminase increase in the DC Bead group
was 50% in the cTACE group (p < 0.001) and 59% for aspartate transaminase
(p < 0.001). For bilirubin, mean increase was 5.30±15.13 vs. 13.53±73.89 µmol/L.
Concerning gastrointestinal disorders, 120 adverse events (AEs) occurred in 57/93
(61.3%) patients in the DC Bead group vs. 114 in 49/108 (45.4%) in cTACE. Concerning
hepatobiliary disorders, serious AEs occurred in 8/93 (8.6%) vs. 11/108
(10.2%) patients. LVEF showed an increase in the DC Bead group by +2.7±10.1
percentage points and a small decrease by -1.5±7.6 in the cTACE group, p=0.018.
Conclusion: PRECISION TACE is safe, even in more advanced HCC patients.
Serious liver and cardiac toxicity were significantly lower in the DC Bead group.
Create date
28/07/2010 8:14
Last modification date
20/08/2019 16:39
Usage data